Nexplanon (Etonogestrel)

Etonogestrel, the active ingredient in Nexplanon, is a progestin presented as a 68 mg subdermal implant for subcutaneous use. It provides long‑acting reversible contraception by preventing ovulation and altering cervical mucus, offering up to three years of pregnancy protection for women of reproductive age.

GNH USA supplies Nexplanon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Etonogestrel is a progestin used in hormonal contraception to prevent pregnancy.

- Prevention of pregnancy (contraception): provides highly effective, reversible contraception for up to three years. - Family planning: enables women to plan and space pregnancies with a single, low‑maintenance device. - Long‑acting reversible contraception: offers a convenient alternative to daily oral pills or monthly injectables.

Nexplanon may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Irregular vaginal bleeding or spotting - Amenorrhea (absence of periods) - Headache - Weight gain - Acne or skin changes - Breast tenderness

Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism - Severe allergic reaction (anaphylaxis, rash, swelling) - Infection at the insertion site - Implant migration or extrusion - Hormonal imbalance causing mood changes - Significant hypertension

Before initiating Nexplanon therapy, several safety considerations should be reviewed.

- Pregnancy testing: confirm the patient is not pregnant prior to insertion. - Smoking: advise women over 35 who smoke to consider alternative methods. - Thromboembolic history: assess for prior clotting disorders or risk factors. - Medication review: evaluate concomitant drugs that may reduce efficacy. - Follow‑up schedule: plan removal or replacement at the three‑year mark. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Etonogestrel can interact with other medicines that affect its metabolism or hormonal activity.

Major Interactions (Avoid): - Rifampin, carbamazepine, phenytoin: strong enzyme inducers that markedly lower implant effectiveness. - St. John's wort: herbal inducer that may reduce plasma levels. - Certain antiretrovirals (e.g., efavirenz): can compromise contraceptive reliability.

Moderate Interactions (Monitor Closely): - Griseofulvin: moderate enzyme inducer, may require additional contraceptive measures. - Antifungal azoles (ketoconazole, itraconazole): may increase hormone levels, monitor for side effects. - Antiepileptic drugs with moderate inducing potential (e.g., phenobarbital): assess efficacy periodically.